Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189 · View on ClinicalTrials.gov ↗
Study Summary
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAT-3247
Study Locations (18)
Other
- Clinic of Neurology and Psychiatry for Children and Youth — Belgrade
- University Children's Clinic Tirsova — Belgrade
- Mother and Child Health Care Institute — Belgrade
California
- University of California Los Angeles — Los Angeles
Colorado
- Colorado Children's — Aurora
Illinois
- Lurie Children's — Chicago
Kansas
- University of Kansas — Kansas City
Maryland
- Kennedy Krieger Institute — Baltimore
Massachusetts
- UMass Memorial Medical Center — Worcester
Missouri
- Washington University — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07287189
The ClinicalTrials.gov registry entry for NCT07287189 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Satellos Bioscience, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07287189 reports 18 study locations spanning 16 distinct geographic areas — top geographies include Other, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07287189 about?
NCT07287189 is a clinical study titled "Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients". Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
What is the current status of trial NCT07287189?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2025-12-08. Estimated completion is 2027-06-30.
What conditions does trial NCT07287189 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Neuromuscular Diseases, Muscular Dystrophies, DMD, Duchenne. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07287189?
The interventions under investigation include: Placebo (DRUG), SAT-3247 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07287189?
This trial is sponsored by Satellos Bioscience, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07287189 being conducted?
This trial has 18 study locations across California, Colorado, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.